U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07323927) titled 'Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease' on Dec. 23, 2025.
Brief Summary: This single-arm, open-label clinical study systematically evaluates the efficacy and safety of Galcanezumab in patients with mild-to-moderate Alzheimer's disease (AD). Eligible participants who provided written informed consent were screened and enrolled to receive Galcanezumab treatment. The therapeutic regimen involved subcutaneous administration of Galcanezumab with an initial 240 mg loading dose followed by 120 mg maintenance doses every four weeks for six total administrations over a 24-week treatment period. All study...